Biologics and Psoriasis : The Beat Goes On - 21/11/18

Doi : 10.1016/j.det.2018.07.004

Hee J. Kim, MD, Mark G. Lebwohl, MD ^⁎
Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, PO Box 1048, New York, NY 10029, USA

^∗Corresponding author.

Résumé

Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

Le texte complet de cet article est disponible en PDF.

Keywords : Biologics, Psoriasis, Psoriatic arthritis, Efficacy, Safety, Th17/IL-23 axis

Plan

Key points

Introduction

Efficacy: PASI-75, PASI-90, and PASI-100

Tumor Necrosis Factor Alpha Inhibitors

Interleukin-12/23, Interleukin-17, and Interleukin-23 Inhibitors

Maintenance of disease control

Interleukin-12/23 Inhibitor

Interleukin-17 Inhibitors

Interleukin-23 Inhibitors

Early onset of efficacy

Safety

Tumor Necrosis Factor Inhibitors

Newer Biologics: Interleukin-12/23, Interleukin-17, and Interleukin-23 Inhibitors

Special population with specific needs

Obesity: Adjust for Weight

Concomitant Psoriatic Arthritis

Safety in Pregnancy

Fewer Injections

Disclosure Statement: Dr M.G. Lebwohl is an employee of Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer and ViDac. Dr M.G. Lebwohl is also a consultant for Allergan, Leopharma, and Promius. Dr H.J. Kim has no financial or commercial conflicting interests to disclose.